Tags

Type your tag names separated by a space and hit enter

Open trial of risperidone in 24 young children with pervasive developmental disorders.
J Am Acad Child Adolesc Psychiatry. 2001 Oct; 40(10):1206-14.JA

Abstract

OBJECTIVE

To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders.

METHOD

Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years +/- 8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS).

RESULTS

Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21% improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based on improvement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10%.

CONCLUSIONS

Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted.

Authors+Show Affiliations

Division of Child Neurology and Psychiatry, University of Pisa, and IRCCS Stella Maris, Calambrone, Italy. masi@inpe.unipi.itNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11589534

Citation

Masi, G, et al. "Open Trial of Risperidone in 24 Young Children With Pervasive Developmental Disorders." Journal of the American Academy of Child and Adolescent Psychiatry, vol. 40, no. 10, 2001, pp. 1206-14.
Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1206-14.
Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2001). Open trial of risperidone in 24 young children with pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 40(10), 1206-14.
Masi G, et al. Open Trial of Risperidone in 24 Young Children With Pervasive Developmental Disorders. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1206-14. PubMed PMID: 11589534.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Open trial of risperidone in 24 young children with pervasive developmental disorders. AU - Masi,G, AU - Cosenza,A, AU - Mucci,M, AU - Brovedani,P, PY - 2001/10/9/pubmed PY - 2001/11/3/medline PY - 2001/10/9/entrez SP - 1206 EP - 14 JF - Journal of the American Academy of Child and Adolescent Psychiatry JO - J Am Acad Child Adolesc Psychiatry VL - 40 IS - 10 N2 - OBJECTIVE: To describe tolerability and efficacy of risperidone in very young children with pervasive developmental disorders. METHOD: Twenty-four children aged 3.6 to 6.6 years (mean 4.6 years +/- 8 months) enrolled during 1999 and 2000 participated in a 16-week open-label trial with risperidone monotherapy. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Childhood Autism Rating Scale (CARS), Clinical Global Impression-Improvement (CGI-I), and Children's Global Assessment Scale (C-GAS). RESULTS: Two subjects did not complete the trial because of side effects. The optimal dose was 0.5 mg/day. After the treatment a 21% improvement in CPRS and a 14% improvement in CARS total scores was found. Items related to behavioral control (hyperactivity, fidgetiness, rhythmic motions) and affect regulation (lability of affect, angry affect) improved more than 25%. Based on improvement of at least 25% on the CPRS and a score of 1 or 2 on the CGI-I, eight subjects were considered responders. Functional impairment (C-GAS) improved more than 25%. Thirteen subjects (54%) were free of any side effects; in the other participants risperidone was well tolerated. Only three subjects had a weight gain greater than 10%. CONCLUSIONS: Low-dose risperidone may positively affect symptoms in young autistic children, improving disruptive/hyperactive behavior and affective dysregulation. Further controlled studies in this age group are warranted. SN - 0890-8567 UR - https://www.unboundmedicine.com/medline/citation/11589534/Open_trial_of_risperidone_in_24_young_children_with_pervasive_developmental_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(09)60496-2 DB - PRIME DP - Unbound Medicine ER -